Skip to main content

Davidson Michael H.'s Form 4 filing

NewAmsterdam Pharma Co N.V.NAMS · filed Feb 26, 2026

Accession no.
0001193125-26-078718
Filed
Feb 26, 2026
Trade date
Feb 24-26, 2026
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 10 non-derivative transactions and 3 derivative transactions. Open-market sales total $10.6M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Davidson Michael H.CIK 0001573785Director, Officer (Chief Executive Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 24, 2026Ordinary SharesMOption exerciseAcquired+64,708–F1–524,567Direct
Feb 24, 2026Ordinary SharesSSaleDisposed−61,547$36.13F2−$2,223,693.11463,020Direct
Feb 24, 2026Ordinary SharesSSaleDisposed−3,161$36.46F3−$115,250.06459,859Direct
Feb 25, 2026Ordinary SharesMOption exerciseAcquired+58,253–F1–518,112Direct
Feb 25, 2026Ordinary SharesSSaleDisposed−46,517$35.11F4−$1,633,211.87471,595Direct
Feb 25, 2026Ordinary SharesSSaleDisposed−10,436$35.96F5−$375,278.56461,159Direct
Feb 25, 2026Ordinary SharesSSaleDisposed−1,300$36.68F6−$47,684459,859Direct
Feb 26, 2026Ordinary SharesMOption exerciseAcquired+183,332–F1–643,191Direct
Feb 26, 2026Ordinary SharesSSaleDisposed−165,408$33.63F7−$5,562,671.04477,783Direct
Feb 26, 2026Ordinary SharesSSaleDisposed−17,924$34.44F8−$617,302.56174,144Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Feb 24, 2026Ordinary SharesMOption exerciseDisposed−64,708$0.00$0924,559Direct
Feb 25, 2026Ordinary SharesMOption exerciseDisposed−58,253$0.00$0866,306Direct
Feb 26, 2026Ordinary SharesMOption exerciseDisposed−183,332$0.00$0682,974Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The exercise price of the option is EUR 1.16392.

Referenced by the price of 3 transactions in Table I.

F2

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.43 to $36.42 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.

Referenced by the price of 1 transaction in Table I.

F3

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.43 to $36.50 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.

Referenced by the price of 1 transaction in Table I.

F4

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.57 to $35.56 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.

Referenced by the price of 1 transaction in Table I.

F5

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.57 to $36.55 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.

Referenced by the price of 1 transaction in Table I.

F6

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.58 to $36.74 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.

Referenced by the price of 1 transaction in Table I.

F7

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.34 to $34.33 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.

Referenced by the price of 1 transaction in Table I.

F8

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.35 to $34.82 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)